Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177367 | 0.92 | AURKA (0.58) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL6750413 | 0.90 | AURKA (0.64) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL12409647 | 0.89 | AURKA (0.58) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL4525559 | 0.86 | CHEK1 (0.72) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL6750540 | 0.85 | AURKA (0.63) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL4527832 | 0.83 | AURKA (0.66) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL6750161 | 0.82 | AURKA (0.66) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL6750552 | 0.82 | AURKA (0.62) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL2180882 | 0.82 | AURKA (0.60) | AURKACHEK1KMT2ARAD52MAP2K1 | |
| SCHEMBL6750415 | 0.81 | AURKA (0.67) | AURKACHEK1KMT2ARAD52MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2008155016-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | AURKA 2987/4885CHEK1 800/4885KMT2A 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.